Case report: Response to endocrine therapy in triple-negative breast cancer metastases with altered hormone receptors
Triple-negative breast cancer refers to breast cancer patients with negative estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER2). Metastatic triple-negative breast cancer is predominantly treated with chemotherapy, but later-line treatment remains cha...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-02-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1023787/full |
| _version_ | 1828033362801983488 |
|---|---|
| author | Ruoyan Qin Jie Qian Mengjun Shan Guangxin Ruan Xiaofeng Yang Yanwen Wang Lingshuang Liu |
| author_facet | Ruoyan Qin Jie Qian Mengjun Shan Guangxin Ruan Xiaofeng Yang Yanwen Wang Lingshuang Liu |
| author_sort | Ruoyan Qin |
| collection | DOAJ |
| description | Triple-negative breast cancer refers to breast cancer patients with negative estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER2). Metastatic triple-negative breast cancer is predominantly treated with chemotherapy, but later-line treatment remains challenging. Breast cancer is highly heterogeneous, and the expression of hormone receptors is often inconsistent between primary and metastatic lesions. Here, we report a case of triple-negative breast cancer 17 years after surgery with lung metastases for 5 years that progressed to pleural metastases after multiple lines of chemotherapy. The pleural pathology suggested ER (+) and PR (+) and transformation to luminal A breast cancer. This patient received fifth-line letrozole endocrine therapy and achieved partial response (PR). The patient’s cough and chest tightness improved after treatment, associated tumor markers decreased, and progression-free survival (PFS) exceeded 10 months. Our results may be of clinical relevance for patients with hormone receptor alterations in advanced triple-negative breast cancer and suggest that individualized regimens should be developed for breast cancer based on the molecular expression of tumor tissue at the primary and metastatic sites. |
| first_indexed | 2024-04-10T15:18:40Z |
| format | Article |
| id | doaj.art-bda475b44fb143f688a2ef15ff8c9524 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-10T15:18:40Z |
| publishDate | 2023-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-bda475b44fb143f688a2ef15ff8c95242023-02-14T17:54:03ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-02-011310.3389/fonc.2023.10237871023787Case report: Response to endocrine therapy in triple-negative breast cancer metastases with altered hormone receptorsRuoyan Qin0Jie Qian1Mengjun Shan2Guangxin Ruan3Xiaofeng Yang4Yanwen Wang5Lingshuang Liu6Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaDepartment of Emergency Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaDepartment of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaDepartment of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaDepartment of Pathology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaDepartment of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaTriple-negative breast cancer refers to breast cancer patients with negative estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER2). Metastatic triple-negative breast cancer is predominantly treated with chemotherapy, but later-line treatment remains challenging. Breast cancer is highly heterogeneous, and the expression of hormone receptors is often inconsistent between primary and metastatic lesions. Here, we report a case of triple-negative breast cancer 17 years after surgery with lung metastases for 5 years that progressed to pleural metastases after multiple lines of chemotherapy. The pleural pathology suggested ER (+) and PR (+) and transformation to luminal A breast cancer. This patient received fifth-line letrozole endocrine therapy and achieved partial response (PR). The patient’s cough and chest tightness improved after treatment, associated tumor markers decreased, and progression-free survival (PFS) exceeded 10 months. Our results may be of clinical relevance for patients with hormone receptor alterations in advanced triple-negative breast cancer and suggest that individualized regimens should be developed for breast cancer based on the molecular expression of tumor tissue at the primary and metastatic sites.https://www.frontiersin.org/articles/10.3389/fonc.2023.1023787/fulltriple-negative breast cancermetastasesaltered hormone receptorslater-line treatmentendocrine therapy |
| spellingShingle | Ruoyan Qin Jie Qian Mengjun Shan Guangxin Ruan Xiaofeng Yang Yanwen Wang Lingshuang Liu Case report: Response to endocrine therapy in triple-negative breast cancer metastases with altered hormone receptors Frontiers in Oncology triple-negative breast cancer metastases altered hormone receptors later-line treatment endocrine therapy |
| title | Case report: Response to endocrine therapy in triple-negative breast cancer metastases with altered hormone receptors |
| title_full | Case report: Response to endocrine therapy in triple-negative breast cancer metastases with altered hormone receptors |
| title_fullStr | Case report: Response to endocrine therapy in triple-negative breast cancer metastases with altered hormone receptors |
| title_full_unstemmed | Case report: Response to endocrine therapy in triple-negative breast cancer metastases with altered hormone receptors |
| title_short | Case report: Response to endocrine therapy in triple-negative breast cancer metastases with altered hormone receptors |
| title_sort | case report response to endocrine therapy in triple negative breast cancer metastases with altered hormone receptors |
| topic | triple-negative breast cancer metastases altered hormone receptors later-line treatment endocrine therapy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1023787/full |
| work_keys_str_mv | AT ruoyanqin casereportresponsetoendocrinetherapyintriplenegativebreastcancermetastaseswithalteredhormonereceptors AT jieqian casereportresponsetoendocrinetherapyintriplenegativebreastcancermetastaseswithalteredhormonereceptors AT mengjunshan casereportresponsetoendocrinetherapyintriplenegativebreastcancermetastaseswithalteredhormonereceptors AT guangxinruan casereportresponsetoendocrinetherapyintriplenegativebreastcancermetastaseswithalteredhormonereceptors AT xiaofengyang casereportresponsetoendocrinetherapyintriplenegativebreastcancermetastaseswithalteredhormonereceptors AT yanwenwang casereportresponsetoendocrinetherapyintriplenegativebreastcancermetastaseswithalteredhormonereceptors AT lingshuangliu casereportresponsetoendocrinetherapyintriplenegativebreastcancermetastaseswithalteredhormonereceptors |